Long-term immunogenicity of influenza vaccine among the elderly: Risk factors for poor immune response and persistence.
about
Fluad®-MF59®-Adjuvanted Influenza Vaccine in Older AdultsWas the mass vaccination effective during the influenza pandemic 2009-2010 in Korea?Evaluation of the Effectiveness of Pandemic Influenza A(H1N1) 2009 Vaccine Based on an Outbreak Investigation During the 2010-2011 Season in Korean Military CampsInnate immune sensing and response to influenza.Seroprotective antibodies to 2011 variant influenza A(H3N2v) and seasonal influenza A(H3N2) among three age groups of US Department of Defense service members.Antibody Persistence in Adults Two Years after Vaccination with an H1N1 2009 Pandemic Influenza Virus-Like Particle Vaccine.Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection.Immunogenicity and safety of trivalent inactivated influenza vaccine: a randomized, double-blind, multi-center, phase 3 clinical trial in a vaccine-limited country.Seroprevalence of pandemic (H1N1) 2009 in pregnant women in China: an observational study.Persistence of immunogenicity of a monovalent influenza virus A/H1N1 2009 vaccine in healthy volunteers.Influenza serological studies to inform public health action: best practices to optimise timing, quality and reporting.Antibody persistence after Pandemic H1N1 2009 influenza vaccination among healthcare workers in Pune, India.Effectiveness of monovalent 2009 pandemic influenza A virus subtype H1N1 and 2010-2011 trivalent inactivated influenza vaccines in Wisconsin during the 2010-2011 influenza season.Phase IV: randomized controlled trial to evaluate lot consistency of trivalent split influenza vaccines in healthy adultsPrevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP) -- United States, 2014-15 influenza season.Complex disease dynamics and the design of influenza vaccination programsSafety and immunogenicity of a new trivalent inactivated split-virus influenza vaccine in healthy Korean children: a randomized, double-blinded, active-controlled, phase III studyFactors associated with maintenance of antibody responses to influenza vaccine in older, community-dwelling adults.Immunogenicity and safety assessment of a trivalent, inactivated split influenza vaccine in Korean children: Double-blind, randomized, active-controlled multicenter phase III clinical trial.Randomized, controlled trial of high-dose influenza vaccine among frail residents of long-term care facilities.Long-Term Immunogenicity and Safety of a Conventional Influenza Vaccine in Patients with Type 2 DiabetesQuantifying the economic value and quality of life impact of earlier influenza vaccination.Influenza Vaccination is Associated with Lower Risk of Acute Coronary Syndrome in Elderly Patients with Chronic Kidney Disease.Persistence of influenza vaccine-induced antibody in lung transplant patients and healthy individuals beyond the season.Immunogenicity and safety of an inactivated trivalent split influenza virus vaccine in young children with recurrent wheezing.Influence of pre-existing hemagglutination inhibition titers against historical influenza strains on antibody response to inactivated trivalent influenza vaccine in adults 50-80 years of age.Traditional and new influenza vaccinesEffects of Repeated Annual Inactivated Influenza Vaccination among Healthcare Personnel on Serum Hemagglutinin Inhibition Antibody Response to A/Perth/16/2009 (H3N2)-like virus during 2010-11.Lack of persistence of influenza vaccine antibody titers in patients with heart failure.The immune response to 6-monthly versus annual standard dose inactivated trivalent influenza vaccination in older people: study protocol for a randomised clinical trial.Waning Immunity and Microbial Vaccines-Workshop of the National Institute of Allergy and Infectious Diseases.Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2017-18 Influenza Season.Effects of prior influenza virus vaccination on maternal antibody responses: Implications for achieving protection in the newborns.Influenza vaccination in the elderly.Prevention and Control of Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices, United States, 2015-16 Influenza Season.Immunogenicity of intradermal trivalent influenza vaccine with topical imiquimod: a double blind randomized controlled trial.Virus-specific antibody secreting cell, memory B-cell, and sero-antibody responses in the human influenza challenge model.Immunogenicity of inactivated seasonal influenza vaccine in adult and pediatric liver transplant recipients over two seasons.The coming era of quadrivalent human influenza vaccines: who will benefit?Prevention and Control of Seasonal Influenza With Vaccines: Recommendations of the Advisory Committee on Immunization Practices-United States, 2017-18 Influenza Season.
P2860
Q27009478-BC85E28F-2F9F-4C1E-A54F-C8A5D7770ED2Q30354918-F162433C-DE09-4EB5-A37D-15A46FB034E1Q30354921-8AB53165-167C-4AD3-91CD-E8D7E8E4FB83Q30365302-AAA40A92-CCE0-4ACD-BDF2-6C4A22665DA0Q30373137-3BDDB245-A5E4-4ABD-9A33-E99415A0DF44Q30384943-67BDCADF-7B2D-421E-9821-9B2FB9542E74Q30398715-D6934164-8925-4DA9-8844-0EEADAF7642AQ30399230-6A91BCFD-43FE-41B4-8EC4-3E2357DDCFCAQ30401153-B008219B-E1AF-4E49-80A8-D413C6E9BDE5Q30411972-6B8D620D-76DD-4E39-AAEE-6EA32E189562Q30416214-F3282C5D-38F8-40C7-82D6-6B36C35CCFEEQ30422077-5F4240CF-6943-4906-A6DB-A764EF64DB13Q30426206-3BEFFAD5-CDC0-4E91-A199-E7678B578845Q33723445-974C18CA-BF8E-4FD2-B4FD-C46ACA964534Q34433508-ED845B51-69F0-4D5B-A6DB-27B4A30D500BQ35047980-C0FEC2AE-1C1F-432B-820D-6A22667689FFQ35511464-580C7AA4-4C79-4F1F-ACF7-E2AE906F934BQ35555742-DBE9EC46-5A5A-42C7-B74A-0201F378400AQ35887773-BEB3B0D0-A6A0-44FB-80F2-3D5205AE8286Q35965224-6BEAC2DA-0E19-4A22-8379-0F67604FED90Q36211642-8554938D-D705-4D43-8246-3BCE4F7FABEEQ36403075-C3BF4AE8-C8E3-4E98-8DD7-9413EC632460Q36566807-D28C2AF7-E6A9-48C3-914E-97500D90576EQ36849805-AE24E5DE-F5C0-4B1D-9FA9-43FA9F24BBCAQ36911322-84EEF0A5-44D9-411C-98BF-7402CE0D1359Q36977899-4B04BEAE-2142-42C9-B3EF-CBF42BC548B1Q37035833-4390E4F5-3707-4561-9A6B-D69208C41D82Q37568436-2C552A2C-2CF5-445D-999C-6E6FE5137913Q37620276-E7BCD27A-55D8-442E-8FB0-2F2CD7E6DDA3Q37635329-E912D9B1-DE98-4CCA-A71E-530E6F814F67Q38685505-46E74777-05DE-4813-872F-2DC8A8C251B7Q40070473-535381FA-151E-4B07-BA7E-D920104079E8Q40094268-78F4DFC9-658B-4E71-A240-B0EE52E640BFQ40134515-A286457B-A162-4FF7-A23D-7B0E147A3D40Q41510283-0321E3E7-B755-494F-A7D3-CFED7C5CB083Q42204647-E89B5D6D-A453-40D2-B5FF-1773963CDBE0Q42243814-387AD052-A313-4DCB-A0F6-2E65156B6C95Q42279569-8053470E-E21E-47A6-9E6D-9647B18D69E0Q42288351-676EFF78-A063-4C44-8018-FB16075E9B5DQ43167908-0155FB1B-75FF-483B-82D6-FD8FE48F6FAF
P2860
Long-term immunogenicity of influenza vaccine among the elderly: Risk factors for poor immune response and persistence.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Long-term immunogenicity of in ...... mune response and persistence.
@en
Long-term immunogenicity of in ...... mune response and persistence.
@nl
type
label
Long-term immunogenicity of in ...... mune response and persistence.
@en
Long-term immunogenicity of in ...... mune response and persistence.
@nl
prefLabel
Long-term immunogenicity of in ...... mune response and persistence.
@en
Long-term immunogenicity of in ...... mune response and persistence.
@nl
P2093
P1433
P1476
Long-term immunogenicity of in ...... mune response and persistence.
@en
P2093
Dae Won Park
Geum Joo Cho
Hee Jin Cheong
In Sook Hwang
Joon Young Song
Taik Gun Hwang
Won Suk Choi
P304
P356
10.1016/J.VACCINE.2010.03.067
P407
P577
2010-04-13T00:00:00Z